Cargando…
A photoaffinity glycan-labeling approach to investigate immunoglobulin glycan-binding partners
Glycans play a pivotal role in biology. However, because of the low-affinity of glycan-protein interactions, many interaction pairs remain unknown. Two important glycoproteins involved in B-cell biology are the B-cell receptor and its secreted counterpart, antibodies. It has been indicated that glyc...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627247/ https://www.ncbi.nlm.nih.gov/pubmed/37498177 http://dx.doi.org/10.1093/glycob/cwad055 |
_version_ | 1785131499848204288 |
---|---|
author | Holborough-Kerkvliet, Miles D Mucignato, Greta Moons, Sam J Psomiadou, Venetia Konada, Rohit S R Pedowitz, Nichole J Pratt, Matthew R Kissel, Theresa Koeleman, Carolien A M Tjokrodirijo, Rayman T N van Veelen, Petrus A Huizinga, Thomas van Schie, Karin A J Wuhrer, Manfred Kohler, Jennifer J Bonger, Kimberly M Boltje, Thomas J Toes, Reinaldus E M |
author_facet | Holborough-Kerkvliet, Miles D Mucignato, Greta Moons, Sam J Psomiadou, Venetia Konada, Rohit S R Pedowitz, Nichole J Pratt, Matthew R Kissel, Theresa Koeleman, Carolien A M Tjokrodirijo, Rayman T N van Veelen, Petrus A Huizinga, Thomas van Schie, Karin A J Wuhrer, Manfred Kohler, Jennifer J Bonger, Kimberly M Boltje, Thomas J Toes, Reinaldus E M |
author_sort | Holborough-Kerkvliet, Miles D |
collection | PubMed |
description | Glycans play a pivotal role in biology. However, because of the low-affinity of glycan-protein interactions, many interaction pairs remain unknown. Two important glycoproteins involved in B-cell biology are the B-cell receptor and its secreted counterpart, antibodies. It has been indicated that glycans expressed by these B-cell-specific molecules can modulate immune activation via glycan-binding proteins. In several autoimmune diseases, an increased prevalence of variable domain glycosylation of IgG autoantibodies has been observed. Especially, the hallmarking autoantibodies in rheumatoid arthritis, anti-citrullinated protein antibodies, carry a substantial amount of variable domain glycans. The variable domain glycans expressed by these autoantibodies are N-linked, complex-type, and α2–6 sialylated, and B-cell receptors carrying variable domain glycans have been hypothesized to promote selection of autoreactive B cells via interactions with glycan-binding proteins. Here, we use the anti-citrullinated protein antibody response as a prototype to study potential in solution and in situ B-cell receptor–variable domain glycan interactors. We employed SiaDAz, a UV-activatable sialic acid analog carrying a diazirine moiety that can form covalent bonds with proximal glycan-binding proteins. We show, using oligosaccharide engineering, that SiaDAz can be readily incorporated into variable domain glycans of both antibodies and B-cell receptors. Our data show that antibody variable domain glycans are able to interact with inhibitory receptor, CD22. Interestingly, although we did not detect this interaction on the cell surface, we captured CD79 β glycan–B-cell receptor interactions. These results show the utility of combining photoaffinity labeling and oligosaccharide engineering for identifying antibody and B-cell receptor interactions and indicate that variable domain glycans appear not to be lectin cis ligands in our tested conditions. |
format | Online Article Text |
id | pubmed-10627247 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106272472023-11-07 A photoaffinity glycan-labeling approach to investigate immunoglobulin glycan-binding partners Holborough-Kerkvliet, Miles D Mucignato, Greta Moons, Sam J Psomiadou, Venetia Konada, Rohit S R Pedowitz, Nichole J Pratt, Matthew R Kissel, Theresa Koeleman, Carolien A M Tjokrodirijo, Rayman T N van Veelen, Petrus A Huizinga, Thomas van Schie, Karin A J Wuhrer, Manfred Kohler, Jennifer J Bonger, Kimberly M Boltje, Thomas J Toes, Reinaldus E M Glycobiology Original Article Glycans play a pivotal role in biology. However, because of the low-affinity of glycan-protein interactions, many interaction pairs remain unknown. Two important glycoproteins involved in B-cell biology are the B-cell receptor and its secreted counterpart, antibodies. It has been indicated that glycans expressed by these B-cell-specific molecules can modulate immune activation via glycan-binding proteins. In several autoimmune diseases, an increased prevalence of variable domain glycosylation of IgG autoantibodies has been observed. Especially, the hallmarking autoantibodies in rheumatoid arthritis, anti-citrullinated protein antibodies, carry a substantial amount of variable domain glycans. The variable domain glycans expressed by these autoantibodies are N-linked, complex-type, and α2–6 sialylated, and B-cell receptors carrying variable domain glycans have been hypothesized to promote selection of autoreactive B cells via interactions with glycan-binding proteins. Here, we use the anti-citrullinated protein antibody response as a prototype to study potential in solution and in situ B-cell receptor–variable domain glycan interactors. We employed SiaDAz, a UV-activatable sialic acid analog carrying a diazirine moiety that can form covalent bonds with proximal glycan-binding proteins. We show, using oligosaccharide engineering, that SiaDAz can be readily incorporated into variable domain glycans of both antibodies and B-cell receptors. Our data show that antibody variable domain glycans are able to interact with inhibitory receptor, CD22. Interestingly, although we did not detect this interaction on the cell surface, we captured CD79 β glycan–B-cell receptor interactions. These results show the utility of combining photoaffinity labeling and oligosaccharide engineering for identifying antibody and B-cell receptor interactions and indicate that variable domain glycans appear not to be lectin cis ligands in our tested conditions. Oxford University Press 2023-07-27 /pmc/articles/PMC10627247/ /pubmed/37498177 http://dx.doi.org/10.1093/glycob/cwad055 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Holborough-Kerkvliet, Miles D Mucignato, Greta Moons, Sam J Psomiadou, Venetia Konada, Rohit S R Pedowitz, Nichole J Pratt, Matthew R Kissel, Theresa Koeleman, Carolien A M Tjokrodirijo, Rayman T N van Veelen, Petrus A Huizinga, Thomas van Schie, Karin A J Wuhrer, Manfred Kohler, Jennifer J Bonger, Kimberly M Boltje, Thomas J Toes, Reinaldus E M A photoaffinity glycan-labeling approach to investigate immunoglobulin glycan-binding partners |
title | A photoaffinity glycan-labeling approach to investigate immunoglobulin glycan-binding partners |
title_full | A photoaffinity glycan-labeling approach to investigate immunoglobulin glycan-binding partners |
title_fullStr | A photoaffinity glycan-labeling approach to investigate immunoglobulin glycan-binding partners |
title_full_unstemmed | A photoaffinity glycan-labeling approach to investigate immunoglobulin glycan-binding partners |
title_short | A photoaffinity glycan-labeling approach to investigate immunoglobulin glycan-binding partners |
title_sort | photoaffinity glycan-labeling approach to investigate immunoglobulin glycan-binding partners |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627247/ https://www.ncbi.nlm.nih.gov/pubmed/37498177 http://dx.doi.org/10.1093/glycob/cwad055 |
work_keys_str_mv | AT holboroughkerkvlietmilesd aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT mucignatogreta aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT moonssamj aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT psomiadouvenetia aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT konadarohitsr aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT pedowitznicholej aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT prattmatthewr aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT kisseltheresa aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT koelemancarolienam aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT tjokrodirijoraymantn aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT vanveelenpetrusa aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT huizingathomas aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT vanschiekarinaj aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT wuhrermanfred aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT kohlerjenniferj aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT bongerkimberlym aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT boltjethomasj aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT toesreinaldusem aphotoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT holboroughkerkvlietmilesd photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT mucignatogreta photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT moonssamj photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT psomiadouvenetia photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT konadarohitsr photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT pedowitznicholej photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT prattmatthewr photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT kisseltheresa photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT koelemancarolienam photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT tjokrodirijoraymantn photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT vanveelenpetrusa photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT huizingathomas photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT vanschiekarinaj photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT wuhrermanfred photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT kohlerjenniferj photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT bongerkimberlym photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT boltjethomasj photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners AT toesreinaldusem photoaffinityglycanlabelingapproachtoinvestigateimmunoglobulinglycanbindingpartners |